[Skip to Navigation]
Sign In
March 16, 2020

Shortcomings in the US Pharmaceutical Supply Chain: Potential Risks Associated With International Manufacturing and Trade-Related Tariffs

Author Affiliations
  • 1James A. Haley Veterans Hospital, Division of Infectious Diseases and International Medicine, University of South Florida Morsani College of Medicine, Tampa
JAMA. 2020;324(2):143-144. doi:10.1001/jama.2020.1634
Add or change institution
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    1 Comment for this article
    Shortcomings in the US Pharmaceutical Supply Chain
    Ramakrishna Hosur, Graduate | Retired regulatory affairs executive
    India in the late 1960's was a producer of basic drugs.Over the years it switched to formulations and now India too is dependent on China as a source of supply. Over 68% of active ingredients are now imported by India from China. This is not secure for the pharma industry to be dependent on one country. On an earlier occasion China used its Rare Earth supply as a trade weapon and there is no guarantee that it will not happen with pharmaceuticals. Nations including the USA should broaden their supply chain in critical areas like pharmaceuticals.